A quantitative evaluation of the effects of l-DOPA on Parkinson's disease
Authors:
- F. VelascoFVF. Velasco
- M. VelascoMVM. Velasco
- 1 February 1973
- journal article
- clinical trial
- Published by Elsevier in Neuropharmacology
- Vol. 12 (2) , 89-99
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Evaluation of Levodopa for Parkinsonism. Levodopa (Dopar, Larodopa)1971
- L-DOPA FOR PROGRESSIVE SUPRANUCLEAR PALSYThe Lancet, 1969
- L-dopa and the negative symptoms of Parkinsonism.Journal of Neurology, Neurosurgery & Psychiatry, 1969
- L-DOPA FOR PROGRESSIVE SUPRANUCLEAR PALSYThe Lancet, 1969
- L-DOPA IN POSTENCEPHALITIC PARKINSONISMThe Lancet, 1969
- Modification of Parkinsonism — Chronic Treatment with L-DopaNew England Journal of Medicine, 1969
- Further observations in progressive supranuclear palsyNeurology, 1968
- Problems in the clinical estimation of rigidity (hypertonia)Clinical Pharmacology & Therapeutics, 1964
- THE NEGATIVE SYMPTOMS OF BASAL GANGLIAR DISEASE: A Survey of 130 Postencephalitic CasesThe Lancet, 1962